Affiliations 

  • 1 National Institute for Biological Standards and Control, Medicines and Healthcare Products Regulatory Agency, Potters Bar, United Kingdom. Electronic address: Meenu.Wadhwa@nibsc.org
  • 2 World Health Organization, Avenue Appia 20, CH-1211, Geneva, Switzerland. Electronic address: kangh@who.int
  • 3 National Biopharmaceutical Facility, King Mongkut's University of Technology Thonburi, Bangkhuntian, Bangkok, 10150, Thailand. Electronic address: teeranart.j@gmail.com
  • 4 International MSD International GmbH, Singapore
  • 5 National Agency of Drug and Food Control (NADFC), Indonesia
  • 6 Brazilian Health Regulatory Agency (ANVISA), Brazil
  • 7 General Directorate of Medicines Supplies and Drugs (DIGEMID), San Miguel, Peru
  • 8 National Medical Products Administration, China
  • 9 Health Sciences Authority, Singapore
  • 10 Zambia Medicines Regulatory Authority, Zambia
  • 11 Food and Drug Administration, Thailand
  • 12 World Health Organization, Philippines
  • 13 Butantan, Brazil
  • 14 Ministry of Food and Drug Safety (MFDS), Republic of Korea
  • 15 Roche Singapore Technical Operations, Singapore
  • 16 National Pharmaceutical Regulatory Agency, Malaysia
  • 17 Iran Food and Drug Administration, Iran
  • 18 International Federation of Pharmaceutical Manufacturers Association, Switzerland
  • 19 Central Administration for Pharmaceutical Affairs, Egypt
  • 20 Mylan Pharmaceuticals Private Limited, India
  • 21 Food & Drug Administration (FDA), USA
  • 22 KOREA VACCINE CO., Republic of Korea
  • 23 Jordan Food and Drug Administration, Jordan
  • 24 Health Canada (HC), Canada
  • 25 Samsung Bioepis, Republic of Korea
  • 26 Federal Service for Surveillance in Healthcare (Roszdravnadzor), Russian Federation
  • 27 Samsung Biologics, Republic of Korea
  • 28 Serum Institute India, India
  • 29 Ministry of Public Health, Thailand
  • 30 World Health Organization, Switzerland
  • 31 GC Cell, Republic of Korea
  • 32 MFDS, Republic of Korea
  • 33 Hugel, Republic of Korea
  • 34 ILDONG Pharmaceutical Co., Ltd, Republic of Korea
  • 35 Novo Nordisk A/S, Denmark
  • 36 Eisai Korea Inc, Republic of Korea
  • 37 ALVOGEN KOREA, Republic of Korea
  • 38 Biocad, Russian Federation
  • 39 LG Chem, Republic of Korea
  • 40 EuBiologics Co., Ltd., Republic of Korea
  • 41 Food and Drugs Authority, Ghana
  • 42 ISU ABXIS Co., Ltd., Republic of Korea
  • 43 The FSBI "SCEEMP of the Ministry of Health of the Russian Federation, Russian Federation
  • 44 F. Hoffmann-La Roche, Ltd., Switzerland
  • 45 Ministry of Health of Ukraine, Ukraine
  • 46 SK Bioscience, Republic of Korea
  • 47 Central Drug Standards Control Organization (CDSCO), India
  • 48 Celltrion, Republic of Korea
  • 49 National Institute for Biological Standards and Control, United Kingdom
  • 50 Pharmaceuticals and Medical Devices Agency (PMDA), Japan
  • 51 GC Pharma, Republic of Korea
  • 52 Handok Inc, Republic of Korea
Biologicals, 2020 May;65:50-59.
PMID: 31959504 DOI: 10.1016/j.biologicals.2019.12.008

Abstract

The first global workshop on implementation of the WHO guidelines on procedures and data requirements for changes to approved biotherapeutic products adopted by the WHO Expert Committee in 2018 was held in June 2019. The workshop participants recognized that the principles based on sound science and the potential for risk, as described in the WHO Guidelines on post-approval changes, which constitute the global standard for product life-cycle management are providing clarity and helping national regulatory authorities in establishing guidance while improving time-lines for an efficient regulation of products. Consequently, the regulatory situation for post-approval changes and guideline implementation is changing but there is a disparity between different countries. While the guidelines are gradually being implemented in some countries and also being considered in other countries, the need for regional workshops and further training on post-approval changes was a common theme reiterated by many participants. Given the complexities relating to post-approval changes in different regions/countries, there was a clear understanding among all participants that an efficient approach for product life-cycle management at a national level is needed to ensure faster availability of high standard, safe and efficacious medicines to patients as per the World Health Assembly Resolution 67.21.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.